drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous, gene-modified T cells engineered to express chimeric antigen receptors that bind surface antigens on malignant B cells in B-cell non-Hodgkin lymphoma, enabling HLA-independent T-cell activation, cytokine release, and cytotoxic tumor cell killing; administered per routine care in this observational study.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-engineered to express chimeric antigen receptors that bind tumor surface antigens (e.g., CD19 on B cells), enabling HLA-independent recognition; CAR signaling activates T cells to proliferate, release cytokines, and exert cytotoxic killing of malignant cells.
drug_name
Chimeric Antigen Receptor T-cells (CAR-T) therapy
nct_id_drug_ref
NCT06156774